KOrean Precision Medicine Networking Group Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Entrectinib (Primary) ; Erlotinib (Primary) ; Pertuzumab (Primary) ; Pertuzumab/trastuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Vemurafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms KOSMOSII
Most Recent Events
- 05 Aug 2024 Planned End Date changed from 1 Sep 2025 to 1 Mar 2027.
- 05 Aug 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2026.
- 06 Jun 2023 As of Feb 2023, 139 of planned 1,000 have been enrolled, according to trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology